Commentary|Articles|August 28, 2025

Experts Highlight Key Topics to Watch at the IASLC 2025 World Conference on Lung Cancer

Fact checked by: Chris Ryan

Experts preview key abstracts to watch at the IASLC 2025 World Conference on Lung Cancer.

The IASLC 2025 World Conference on Lung Cancer (WCLC) is set to showcase key updates across thoracic oncology, including the evolving management of EGFR-mutated and ROS1-positive non–small cell lung cancer (NSCLC), advances in small cell lung cancer (SCLC), and the expanding role of antibody-drug conjugates (ADCs).

Related to this article

2026 IASLC WCLC Conference Recap | Image Credit: © Ashling Wahner & MJH Life Sciences Using AI

October 8th, 2026

MAVERICK, B7-H3–Directed ADCs, and ADAURA Data Headline Key Lung Cancer Findings From WCLC 2026

Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.

Image by Ashling Wahner & MJH Life Sciences Using AI

October 9th, 2026

Targeted Approaches in Pancreatic Cancer, Chemo Intensification in CRC Take Center Stage as Key GI Oncology Presentations at ESMO 2026

Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.

October 9th, 2026

OncLive Weekly News Quiz (10/9/2026): Did You Miss Crucial Colon Cancer, Myeloma, Breast Cancer, and Lung Cancer Updates?

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.

October 7th, 2026

September Roundup of FDA Approvals in Oncology: 8 Decisions to Know

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.

October 7th, 2026

FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC

The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.

Myeloma | Image Credit: Tongpoon - stock.adobe.com

October 7th, 2026

Etentamig, Iberdomide, and Long-Term PERSEUS Data Headline Key Myeloma Findings From IMS 2026

Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.

October 6th, 2026

Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC

Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.

October 6th, 2026

Next-Generation CTLA-4 Targeting Frames Post-Immunotherapy Squamous NSCLC Management

Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.